SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 6-K

 

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-163

UNDER THE SECURITIES EXCHANGE ACT OF 1934

 

For the month of February 2025

 

Alterity Therapeutics Limited

(Name of Registrant)

 

Level 14, 350 Collins Street, Melbourne, Victoria 3000 Australia

(Address of Principal Executive Office)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

 

Form 20-F ☒       Form 40-F ☐

 

This Form 6-K is being incorporated by reference into our Registration Statement on Form S-8 (Files No. 333-251073, 333-248980 and 333-228671) and our Registration Statements on Form F-3 (Files No. 333-274816, 333-251647, 333-231417 and 333-250076)

 

 

 

 

 

 

ALTERITY THERAPEUTICS LIMITED

(a development stage enterprise)

 

The following exhibits are submitted:

 

99.1  

Change in substantial holding

 

1

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  Alterity Therapeutics Limited
     
  By: /s/ Geoffrey P. Kempler
    Geoffrey P. Kempler
    Chairman

 

Date: February 19, 2025

 

 

2

 

Exhibit 99.1

 

 

Form 604

 

Corporations Act 2001
Section 671B

 

Notice of change of interests of substantial holder

 

 

To  Company Name/Scheme   Alterity Therapeutics Limited 
ACN/ARSN   080 699 065

  

1. Details of substantial holder (1)

 

Name   The Bank of New York Mellon Corporation (BNYMC) and each Group Entity listed in Annexure A (Group Entity),(together BNYMC Group)
ACN/ARSN (if applicable)    

 

There was a change in the interests of the substantial holder on   17/February/2025
The previous notice was given to the company on   04/February/2025
The previous notice was dated   03/February/2025

  

2. Previous and present voting power

 

The total number of votes attached to all the voting shares in the company or voting interests in the scheme that the substantial holder or an associate (2) had a relevant interest (3) in when last required, and when now required, to give a substantial holding notice to the company or scheme, are as follows:

 

Class of securities (4) Previous notice Present notice
  Person’s votes Voting power (5) Person’s votes Voting power (5)
Ordinary shares 2,266,681,474 41.28% 2,260,546,474* 33.96%*
      *See Note 1 in Annexure C  

  

3. Changes in relevant interests

 

Particulars of each change in, or change in the nature of, a relevant interest of the substantial holder or an associate in voting securities of the company or scheme, since the substantial holder was last required to give a substantial holding notice to the company or scheme are as follows:

 

Date of change Person whose relevant interest changed Nature of change (6) Consideration given in relation to change (7) Class and number of securities affected Person’s votes affected
See Annexure B          
           
           

  

Page 1 of 6

 

 

4. Present relevant interests

 

Particulars of each relevant interest of the substantial holder in voting securities after the change are as follows:

 

Holder of relevant interest Registered holder of securities Person entitled to be registered as holder (8) Nature of relevant interest (6) Class and number of securities Person’s votes
See Annexure C          
           
           

  

5. Changes in association

 

The persons who have become associates (2) of, ceased to be associates of, or have changed the nature of their association (9) with, the substantial holder in relation to voting interests in the company or scheme are as follows:

 

Name and ACN/ARSN (if applicable) Nature of association
BNYMC and each Group Entity

Each Group Entity is an associate of BNYMC pursuant to section 12(2)(a) of the Corporations Act 2001 (Cth) as each entity is directly or indirectly owned and controlled by BNYMC.

   

  

6. Addresses

 

The addresses of persons named in this form are as follows:

 

Name Address

The Bank of New York Mellon Corporation

240 Greenwich Street, New York, NY 10286 USA
Each Group Entity 240 Greenwich Street, New York, NY 10286 USA

 

 

Signature 

 

print name Andrew Weiser   capacity Attorney-In-Fact
         
sign here /s/ Andrew Weiser   date 18/February/2025

 

Page 2 of 6

 

 

Annexure A

 

This is Annexure A of 1 page referred to in Form 604 Notice of Change of Interests of Substantial Holder given by The Bank of New York Mellon Corporation and its related bodies corporate.

 

The Bank of New York Mellon Corporation is the ultimate parent company of a corporate group comprised of a large number of operating and holding companies. Details of the entities directly owned and controlled by The Bank of New York Mellon Corporation are listed below.

 

·The Bank of New York Mellon
·Pershing Group LLC
·Pershing LLC

 

print name Andrew Weiser   capacity Attorney-In-Fact
         
sign here /s/ Andrew Weiser   date 18/February/2025

 

Page 3 of 6

 

 

Annexure B

 

This is Annexure B of 1 page referred to in Form 604 Notice of Change of Interests of Substantial Holder given by The Bank of New York Mellon Corporation and its related bodies corporate

 

Changes in relevant interests

 

Date of change

Person whose relevant interest changed

Nature of Change

Consideration given in

relation to change

Class and number of
securities affected

(Ordinary Shares)

Person’s votes affected
4-Feb-2025 The Bank of New York Mellon Transfer Out of securities N/A (9,732,000) (9,732,000)
5-Feb-2025 The Bank of New York Mellon Transfer Out of securities N/A (3,600,000) (3,600,000)
5-Feb-2025 The Bank of New York Mellon Deposit of securities N/A 2,697,000  2,697,000 
13-Feb-2025 The Bank of New York Mellon Deposit of securities N/A 4,500,000  4,500,000 

 

Print Name - Andrew Weiser   Capacity - Attorney-In-Fact
         
Sign Here /s/ Andrew Weiser   Date - 18 February 2025

 

Page 4 of 6

 

 

Annexure C

 

This is Annexure C of 2 pages referred to in Form 604 Notice of Change of Interests of Substantial Holder given by The Bank of New York Mellon Corporation and its related bodies corporate

 

Present relevant interests

 

Holder of relevant interest Nature of relevant interest Class and number of securities
The Bank of New York Mellon (BNYM)

Remote Interest Held Under Deposit Agreement

 

Relevant interest under section 608(1)(c) of the Corporations Act 2001 (Cth) arising from BNYM having the limited power to dispose of, or control the exercise of a power to dispose of, securities deposited with or held by BNYM (or its custodian or agent) in its capacity as depositary administering an ADR program for Alterity Therapeutics Limited (Company) under the Deposit Agreement dated January 2, 2008 between the Company, holders of American depositary receipts (ADRs) and BNYM (Deposit Agreement). [*See Note 1 below].

2,260,545,748

ordinary shares

BNYMC Group (other than BNYM) Relevant interest under section 608(3)(a) and/or section 608(3)(b) of the Corporations Act 2001 (Cth) being a relevant interest held through a body corporate (namely BNYM) in which the voting power of each other entity in the BNYMC Group is above 20%, or that each other entity in the BNYMC Group controls. [*See Note 1 and Note 2 below]

2,260,545,748

ordinary shares

Pershing LLC Relevant interest under sections 608(1) of the Corporations Act 2001 (Cth) arising from Pershing LLC being the registered owner of the securities. 726 ordinary shares
BNYMC Group (other than Pershing LLC)

Relevant interest under section 608(3)(a) and/or section 608(3)(b) of the Corporations Act 2001 (Cth) being a relevant interest held through a body corporate (namely Pershing LLC) in which the voting power of each other entity in the BNYMC Group is above 20%, or that each other entity in the BNYMC Group controls.

[*See Note 2 below]

726 ordinary shares

  

Page 5 of 6

 

 

NOTES:

 

*Note 1: Of the total of 2,260,546,474 securities in which the BNYMC Group has a relevant interest, BNYM has a relevant interest in 2,260,545,748 securities as depositary for Alterity Therapeutics Limited ADR program administered under the Deposit Agreement. BNYM’s relevant interest in these securities arises as a result of the Deposit Agreement containing rights for BNYM to dispose of securities held under the ADR program in limited circumstances. Under the Deposit Agreement, ADR holders retain their rights to dispose of those securities and to give voting instructions for the exercise of voting rights attached to the securities. BNYMC Group’s power to vote or dispose of these securities is qualified accordingly.

 

*Note 2: Each Group Entity is a direct or indirect wholly owned subsidiary of BNYMC, the ultimate parent company. Other than BNYM in respect of 2,260,545,748 securities (of which BNYM’s power to only dispose of 2,260,545,748 securities is limited – see Note 1), and Pershing LLC in respect of 726 securities, none of the BNYMC Group entities are entitled to be registered as holder of the securities and their power to vote or dispose of the securities is qualified accordingly.

  

print name  Andrew Weiser capacity Attorney-In-Fact
     
sign here /s/ Andrew Weiser   date 18/February/2025

 

Page 6 of 6

 


Alterity Therapeutics (PK) (USOTC:PRNAF)
Graphique Historique de l'Action
De Fév 2025 à Mar 2025 Plus de graphiques de la Bourse Alterity Therapeutics (PK)
Alterity Therapeutics (PK) (USOTC:PRNAF)
Graphique Historique de l'Action
De Mar 2024 à Mar 2025 Plus de graphiques de la Bourse Alterity Therapeutics (PK)